




PHARMACEUTICAL 2020

Adamas Pharmaceuticals Inc
Rank 288 of 358





PHARMACEUTICAL 2020

Adamas Pharmaceuticals Inc Rank 288 of 358

The relative strengths and weaknesses of Adamas Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Adamas Pharmaceuticals Inc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 27% points. The greatest weakness of Adamas Pharmaceuticals Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 151% points.

The company's Economic Capital Ratio, given in the ranking table, is -66%, being 102% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	150,320
Cost of Goods Sold	2,469
Intangible Assets	0
Liabilities, Current	26,948
Liabilities, Non-Current	136,103
Other Assets	9,389
Other Compr. Net Income	280
Other Expenses	12,951
Other Liabilities	0
Other Net Income	0
Other Revenues	54,637
Property and Equipment	2,449
Research and Development	30,034
Selling, General and Administrative Expense	114,369

Output Variable	Value in 1000 USD
Assets	162,158
Liabilities	163,051
Expenses	159,823
Revenues	54,637
Stockholders Equity	-893
Net Income	-105,186
Comprehensive Net Income	-105,046
Economic Capital Ratio	-66%